Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma

Table 1

Demographics, presentations, treatments, and outcomes of reported cases of metastatic EC.

Serial number	Age/sex [reference]	Presentation of primary cutaneous lesion	Metastatic sites	Treatment	Outcome
1	60/F [5]	Ulcerative, nodular, scaly, erythematous	Axillary and subclavicular LNs	Capecitabine	PFS (18 months)
2	73/M [12]	Ulcerative, nodular, erythematous	Parotid gland, cervical LNs, lung	Capecitabine	CR
3	64/F [13]	ND	Intraparotid LN	Tamoxifen	PFS (3 years)
4	43/F [10]	ND	Occipital LNs, cervical nerve root, vertebrae	Sunitinib	PFS (8 months)
5	45/F [11]	ND	Cervical LNs, bone, choroid	Doxorubicin	POD (deceased after 2 months)
6	59/F [4]	Bluish nodule, 2 cm diameter	Mediastinal LNs, lung	Cyclophosphamide	POD (deceased after 1 month)

CR: complete response; F: female; LN: lymph node; M: male; ND: not described; PFS: progression free survival; POD: progression of disease.